Bob
Have a question related to this hub?
Alice
Got something to say related to this hub?
Share it here.
![]() | |
Clinical data | |
---|---|
Other names | DAM-57; N,N-Dimethyllysergamide; DAM; Lysergic acid dimethylamide |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | hepatic |
Excretion | renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H21N3O |
Molar mass | 295.386 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
DAM-57, also known as N,N-dimethyllysergamide (DAM) or as lysergic acid dimethylamide, is a derivative of ergine. There has been a single report of observing N,N-dimethyl-D-lysergamide in the illicit drug market.[1] This compound did induce autonomic disturbances at oral levels of some ten times the dosage required for lysergic acid diethylamide (LSD), presumably in the high hundreds of micrograms. There is some disagreement as to whether there were psychic changes observed.[2] It was first described in the scientific literature by Albert Hofmann and colleagues by 1955.[3]